Evidence map›Paper›PMID 41240154›Full record

ArticleJournal of clinical immunology2025

Bronchiectasis, Low IgG Levels and Lack of Vaccination are Risk Factors for Covid-19 Hospitalization in X-linked Agammaglobulinemia - A Retrospective Multicenter Study.

Caroline Stenlander, Hannes Lindahl, Emelie Wahren-Borgström, Christoph B Geier, Anna Sediva, Børre Fevang, Cinzia Milito, Cláudia Varandas, Cristina Roca-Oporto, Federica Pulvirenti and 17 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Caroline StenlanderDepartment of Laboratory Medicine, Clinical Immunology, Karolinska Institutet, Stockholm, Sweden.
Hannes LindahlDepartment of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
Emelie Wahren-BorgströmDepartment of Laboratory Medicine, Clinical Immunology, Karolinska Institutet, Stockholm, Sweden.
Christoph B GeierDivision of Immunology, Faculty of Medicine and Health Sciences, University Medicine Oldenburg, Oldenburg, Germany.
Anna SedivaDepartment of Immunology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Børre FevangSection of Clinical Immunology and Infectious Diseases, Division of Surgery and Specialized Medicine, Oslo University Hospital, Oslo, Norway.
Cinzia MilitoDepartment of Molecular Medicine, Sapienza University, Rome, Italy.
Cláudia VarandasULS Santa Maria, Hospital de Santa Maria, Lisbon, Portugal.
Cristina Roca-OportoClinical Unit of Infectious Diseases, Microbiology and Parasitology, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocio, Seville, Spain.
Federica PulvirentiReference Centre for Primary Immune Deficiencies, Sapienza University Hospital Policlinico Umberto I, Rome, Italy.
Isabel HodlDivision of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Ivana MalkusovaDepartment of Immunology and Allergology, Faculty of Medicine, Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czechia.
Jacques G RivièreInfection and Immunity in Pediatric Patients Research Group, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Catalonia, Spain.
Jiri LitzmanDepartment of Clinical Immunology and Allergology, St. Anne's University in Brno, Brno, Czechia.
Jolan E WalterDivision of Pediatric Allergy & Immunology, Department of Pediatrics, University of South Florida, Tampa, FL, USA.
Leif G HanitschInstitute for Medical Immunology, Charité Universitaetsmedizin, Berlin, Germany.
Olaf NethPaediatric Infectious Diseases, Rheumatology and Immunology Unit, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocio, University of Seville/CSIC, Seville, Spain.
Pavlina KralickovaInstitute of Clinical Immunology and Allergy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
Rahim MillerDivision of Pediatric Allergy & Immunology, Department of Pediatrics, University of South Florida, Tampa, FL, USA.
Serena ShaffrenDivision of Pediatric Allergy & Immunology, Department of Pediatrics, University of South Florida, Tampa, FL, USA.
Susana L SilvaULS Santa Maria, Hospital de Santa Maria, Lisbon, Portugal.
Terese KatzensteinDepartment of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Timi MarteliusInflammation Center, Infectious Diseases, HUS Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Urs C SteinerDepartment of Clinical Immunology, University Hospital Zurich, Zurich, Switzerland.
C I Edvard SmithDepartment of Laboratory Medicine, Clinical Immunology, Karolinska Institutet, Stockholm, Sweden.
Klaus WarnatzCenter for Chronic Immunodeficiency (CCI), Medical Center, University of Freiburg, Freiburg, Germany. klaus.warnatz@uniklinik-freiburg.de.
Peter BergmanDepartment of Laboratory Medicine, Clinical Immunology, Karolinska Institutet, Stockholm, Sweden. peter.bergman@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-linked agammaglobulinemia (XLA) is caused by loss-of-function variants in Bruton's tyrosine kinase, leading to absence of circulating B lymphocytes and inability to produce antibodies. Despite the fear that patients with XLA would be at high risk for severe infection when the novel virus SARS-CoV-2 emerged in the society with low pre-existing immunity, most patients with XLA did not suffer from severe disease. However, some patients were critically affected. Factors associated with hospitalization in patients with XLA remain poorly described. Thus, we designed a study to determine risk factors associated with hospitalization due to Covid-19 in patients with XLA. Data was collected from 17 sites in Europe and the US, comprising n = 81 patients, with hospitalization due to SARS-CoV-2 infection in 14 patients. Nearly 17% of patients with XLA required hospitalization due to Covid-19, but only 3 patients had ventilatory support. After correcting for the effect of the date of infection during the early pandemic, univariate and multiple logistic regression analysis showed that preexisting bronchiectasis and lower IgG serum trough levels (< 8 g/L) before infection were associated with an increased risk for hospitalization, with a high rate of superinfection. The lack of vaccination seemed to contribute to this risk, and ambulatory patients had higher amounts of CD4

Indexed as

AgammaglobulinemiaBronchiectasisCOVID-19Genetic Diseases, X-LinkedHospitalizationImmunoglobulin GSARS-CoV-2AdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsVaccinationImmunoglobulin GBronchiectasisCovid-19IgG trough levelsSARS CoV-2VaccinationX-linked agammaglobulinemia

Identifiers

PMID41240154
PMCPMC12619783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.